Latest Breaking News On - Domain niemann pick - Page 1 : vimarsana.com

Cyclo Therapeutics (CYTH) Reports Publication of Data from Phase 2 Study of Trappsol Cyclo

Cyclo Therapeutics (CYTH) Reports Publication of Data from Phase 2 Study of Trappsol Cyclo
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCaroline hastingsJenene thomasCompany trappsolCompany phaseGlobal principal investigator for the companyProgram steering committeeCyclo therapeutics incExchange commissionCyclo therapeuticsMolecular geneticsGlobal principal investigatorScott fineChief executive officerDomain niemann pickClinical severity scale

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

– Data published in official journal of Molecular Genetics and Metabolism Reports: Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion Trappsol® Cyclo™ was detected in the CSF Completers had an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical Severity Scale (17D-NPC-CSS) Improvement in Scale Assessment and Rating of Ataxia (SARA) score for the mean score in 7 of 8 domains at Week 48 compared with baseline Demonstrated a favorable benefit-risk profile

United statesCaroline hastingsCompany phaseGlobal principal investigator for the companyProgram steering committeeExchange commissionCyclo therapeutics incCompany trappsolCyclo therapeuticsMolecular geneticsGlobal principal investigatorChief executive officerDomain niemann pickClinical severity scaleOrphan drug designationFast track